CytomX Q3 2025 revenue $6.0M (down 82% YoY); cash $143.6M; pipeline on track for key milestones

CytomX Therapeutics, Inc.

Total revenue $6.0M in Q3 2025 vs $33.4M in Q3 2024; cash, equivalents and investments $143.6M, runway to Q2 2027.
R&D expenses $15.3M (-$6.1M YoY); G&A $6.4M (-$1.5M YoY); total operating expense $21.7M.
CX-2051 Phase 1 enrollment ~100 patients by Q1 2026 data update; Phase 1b combo with bevacizumab starts Q1 2026.
CX-801 Phase 1 monotherapy biomarker data at SITC 2025; combo with KEYTRUDA dose escalation enrolling 2nd dose level.
Appointed Rachael Lester as SVP, Chief Business Officer in October 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.